Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project.
Ingrasciotta Y, Spini A, L'Abbate L, Fiore ES, Carollo M, Ientile V, Isgrò V, Cavazzana A, Biasi V, Rossi P, Ejlli L, Belleudi V, Poggi F, Sapigni E, Puccini A, Ancona D, Stella P, Pollina Addario S, Allotta A, Leoni O, Zanforlini M, Tuccori M, Gini R, Trifirò G. Ingrasciotta Y, et al. Among authors: puccini a. Pharmacol Res. 2024 Feb;200:107074. doi: 10.1016/j.phrs.2024.107074. Epub 2024 Jan 15. Pharmacol Res. 2024. PMID: 38232909 Free article.
Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures.
Lapi F, Cipriani F, Caputi AP, Corrao G, Vaccheri A, Sturkenboom MC, Di Bari M, Gregori D, Carle F, Staniscia T, Vestri A, Brandi M, Fusco V, Campisi G, Mazzaglia G; Bisphosphonates Efficacy-Safety Tradeoff (BEST) study group. Lapi F, et al. Osteoporos Int. 2013 Feb;24(2):697-705. doi: 10.1007/s00198-012-2013-y. Epub 2012 May 23. Osteoporos Int. 2013. PMID: 22618266
Risk of severe upper gastrointestinal complications among oral bisphosphonate users.
Ghirardi A, Scotti L, Zambon A, Della Vedova G, Cavalieri D'oro L, Lapi F, Cipriani F, Caputi AP, Vaccheri A, Gregori D, Gesuita R, Vestri A, Staniscia T, Mazzaglia G, Corrao G; BEST Investigators. Ghirardi A, et al. PLoS One. 2013 Dec 9;8(12):e73159. doi: 10.1371/journal.pone.0073159. eCollection 2013. PLoS One. 2013. PMID: 24348985 Free PMC article.
Effectiveness of oral bisphosphonates for primary prevention of osteoporotic fractures: evidence from the AIFA-BEST observational study.
Ghirardi A, Di Bari M, Zambon A, Scotti L, Della Vedova G, Lapi F, Cipriani F, Caputi AP, Vaccheri A, Gregori D, Gesuita R, Vestri A, Staniscia T, Mazzaglia G, Corrao G; BEST investigators. Ghirardi A, et al. Eur J Clin Pharmacol. 2014 Sep;70(9):1129-37. doi: 10.1007/s00228-014-1708-8. Epub 2014 Jun 22. Eur J Clin Pharmacol. 2014. PMID: 24951915
Trends in paediatric macrolide use in five European countries-a population-based study.
Holstiege J, Enders D, Schink T, Innocenti F, Oteri A, Bezemer I, Kaguelidou F, Molokhia M, Poluzzi E, Puccini A, Ulrichsen SP, Sturkenboom MC, Trifirò G, Garbe E. Holstiege J, et al. Among authors: puccini a. Eur J Clin Pharmacol. 2015 Aug;71(8):991-9. doi: 10.1007/s00228-015-1870-7. Epub 2015 May 22. Eur J Clin Pharmacol. 2015. PMID: 25998220
118 results